Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.

  • 1.

    MehtaJWangHIqbalSUMesaR. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma2014;55:595600.

  • 2.

    AndersonLAJamesGDuncombeAS. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol2015;90:864870.

    • Search Google Scholar
    • Export Citation
  • 3.

    MesaRMillerCBThyneM. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer2016;16:167.

    • Search Google Scholar
    • Export Citation
  • 4.

    KundrandaMNTibesRMesaRA. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?Curr Hematol Malig Rep2012;7:7886.

    • Search Google Scholar
    • Export Citation
  • 5.

    GeyerHLScherberRMDueckAC. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood2014;123:38033810.

    • Search Google Scholar
    • Export Citation
  • 6.

    PriceGLDavisKLKarveS. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One2014;9:e90299.

    • Search Google Scholar
    • Export Citation
  • 7.

    ArberDAOraziAHasserjianR. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood2016;127:23912405.

    • Search Google Scholar
    • Export Citation
  • 8.

    TefferiA. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol2016;91:5058.

  • 9.

    SteinBLGotlibJArcasoyM. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw2015;13:424434.

    • Search Google Scholar
    • Export Citation
  • 10.

    BaxterEJScottLMCampbellPJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet2005;365:10541061.

    • Search Google Scholar
    • Export Citation
  • 11.

    KralovicsRPassamontiFBuserAS. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med2005;352:17791790.

  • 12.

    LevineRLWadleighMCoolsJ. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell2005;7:387397.

    • Search Google Scholar
    • Export Citation
  • 13.

    ScottLMTongWLevineRL. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med2007;356:459468.

  • 14.

    PietraDLiSBrisciA. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood2008;111:16861689.

    • Search Google Scholar
    • Export Citation
  • 15.

    PardananiADLevineRLLashoT. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood2006;108:34723476.

    • Search Google Scholar
    • Export Citation
  • 16.

    PikmanYLeeBHMercherT. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med2006;3:e270.

  • 17.

    BeerPACampbellPJScottLM. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood2008;112:141149.

  • 18.

    GuglielmelliPPancrazziABergamaschiG. Anaemia characterises patients with myelofibrosis harbouring MPL mutation. Br J Haematol2007;137:244247.

    • Search Google Scholar
    • Export Citation
  • 19.

    KlampflTGisslingerHHarutyunyanAS. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med2013;369:23792390.

  • 20.

    NangaliaJMassieCEBaxterEJ. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med2013;369:23912405.

    • Search Google Scholar
    • Export Citation
  • 21.

    PietraDRumiEFerrettiVV. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia2016;30:431438.

    • Search Google Scholar
    • Export Citation
  • 22.

    TefferiALashoTLFinkeC. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia2014;28:15681570.

    • Search Google Scholar
    • Export Citation
  • 23.

    TefferiALashoTLTischerA. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood2014;124:24652466.

    • Search Google Scholar
    • Export Citation
  • 24.

    RumiEPietraDPascuttoC. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood2014;124:10621069.

  • 25.

    TefferiALashoTLFinkeCM. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia2014;28:14721477.

    • Search Google Scholar
    • Export Citation
  • 26.

    Milosevic FeenstraJDNivarthiHGisslingerH. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood2016;127:325332.

    • Search Google Scholar
    • Export Citation
  • 27.

    NangaliaJGreenTR. The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program2014;2014:287296.

    • Search Google Scholar
    • Export Citation
  • 28.

    RampalRAhnJAbdel-WahabO. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A2014;111:E54015410.

    • Search Google Scholar
    • Export Citation
  • 29.

    VardimanJWHarrisNLBrunningRD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood2002;100:22922302.

  • 30.

    VardimanJWThieleJArberDA. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood2009;114:937951.

    • Search Google Scholar
    • Export Citation
  • 31.

    BarbuiTThieleJVannucchiAMTefferiA. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J2015;5:e337.

    • Search Google Scholar
    • Export Citation
  • 32.

    VannucchiAMLashoTLGuglielmelliP. Mutations and prognosis in primary myelofibrosis. Leukemia2013;27:18611869.

  • 33.

    GuglielmelliPLashoTLRotunnoG. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia2014;28:18041810.

    • Search Google Scholar
    • Export Citation
  • 34.

    MesaRAVerstovsekSCervantesF. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res2007;31:737740.

    • Search Google Scholar
    • Export Citation
  • 35.

    BarbuiTThieleJPassamontiF. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol2011;29:31793184.

    • Search Google Scholar
    • Export Citation
  • 36.

    BarbuiTThieleJGisslingerH. Masked polycythemia vera (mPV): results of an international study. Am J Hematol2014;89:5254.

  • 37.

    BarosiGMesaRAThieleJ. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia2008;22:437438.

    • Search Google Scholar
    • Export Citation
  • 38.

    McMahonBSteinBL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost2013;39:101111.

    • Search Google Scholar
    • Export Citation
  • 39.

    KaifieAKirschnerMWolfD. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol2016;9:18.

    • Search Google Scholar
    • Export Citation
  • 40.

    FedericiABRandJHBucciarelliP. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost2000;84:345349.

  • 41.

    LippiGFranchiniMSalvagnoGL. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma. J Thromb Thrombolysis2008;26:150153.

    • Search Google Scholar
    • Export Citation
  • 42.

    MesaRANiblackJWadleighM. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer2007;109:6876.

    • Search Google Scholar
    • Export Citation
  • 43.

    MesaRASchwagerSRadiaD. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res2009;33:11991203.

    • Search Google Scholar
    • Export Citation
  • 44.

    MesaRAKantarjianHTefferiA. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117:48694877.

    • Search Google Scholar
    • Export Citation
  • 45.

    ScherberRDueckACJohanssonP. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood2011;118:401408.

    • Search Google Scholar
    • Export Citation
  • 46.

    EmanuelRMDueckACGeyerHL. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol2012;30:40984103.

    • Search Google Scholar
    • Export Citation
  • 47.

    MesaRAGotlibJGuptaV. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol2013;31:12851292.

    • Search Google Scholar
    • Export Citation
  • 48.

    TefferiAGuglielmelliPLarsonDR. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood2014;124:25072513; quiz 2615.

    • Search Google Scholar
    • Export Citation
  • 49.

    GuglielmelliPRotunnoGFanelliT. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J2015;5:e360.

    • Search Google Scholar
    • Export Citation
  • 50.

    PanagiotaVTholFMarkusB. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia2014;28:15521555.

    • Search Google Scholar
    • Export Citation
  • 51.

    GuglielmelliPBiamonteFScoreJ. EZH2 mutational status predicts poor survival in myelofibrosis. Blood2011;118:52275234.

  • 52.

    TefferiAJimmaTSulaiNH. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia2012;26:475480.

    • Search Google Scholar
    • Export Citation
  • 53.

    LundbergPKarowANienholdR. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood2014;123:22202228.

    • Search Google Scholar
    • Export Citation
  • 54.

    TefferiAGuglielmelliPLashoTL. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia2014;28:14941500.

    • Search Google Scholar
    • Export Citation
  • 55.

    CervantesFDupriezBPereiraA. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood2009;113:28952901.

    • Search Google Scholar
    • Export Citation
  • 56.

    PassamontiFCervantesFVannucchiAM. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood2010;115:17031708.

    • Search Google Scholar
    • Export Citation
  • 57.

    GangatNCaramazzaDVaidyaR. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol2011;29:392397.

    • Search Google Scholar
    • Export Citation
  • 58.

    VannucchiAMGuglielmelliPRotunnoG. Mutation-enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM and IWG-MRT Project [abstract]. Blood2014;124:Abstract 405.

    • Search Google Scholar
    • Export Citation
  • 59.

    TefferiAGuglielmelliPFinkeC. Integration of mutations and karyotype towards a Genetics-Based Prognostic Scoring System (GPSS) for primary myelofibrosis [abstract]. Blood2014;124:Abstract 406.

    • Search Google Scholar
    • Export Citation
  • 60.

    PatnaikMMCaramazzaDGangatN. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol2010;84:105108.

    • Search Google Scholar
    • Export Citation
  • 61.

    TefferiASiragusaSHusseinK. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype. Am J Hematol2010;85:1417.

    • Search Google Scholar
    • Export Citation
  • 62.

    HusseinKPardananiADVan DykeDL. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood2010;115:496499.

    • Search Google Scholar
    • Export Citation
  • 63.

    CaramazzaDBegnaKHGangatN. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia2011;25:8288.

    • Search Google Scholar
    • Export Citation
  • 64.

    TefferiABarosiGMesaRA. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood2006;108:14971503.

    • Search Google Scholar
    • Export Citation
  • 65.

    TefferiACervantesFMesaR. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood2013;122:13951398.

    • Search Google Scholar
    • Export Citation
  • 66.

    JabbourEKantarjianHCortesJ. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer2007;110:20122018.

    • Search Google Scholar
    • Export Citation
  • 67.

    SilverRTVandrisKGoldmanJJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood2011;117:66696672.

    • Search Google Scholar
    • Export Citation
  • 68.

    SilverRTFeldmanEJRitchieE. Recombinant interferon alpha (rIFN) may retard progression of early myelofibrosis by reducing splenomegaly and by decreasing marrow fibrosis [abstract]. Blood2013;122:Abstract 4053.

    • Search Google Scholar
    • Export Citation
  • 69.

    IanottoJCBoyer-PerrardFGyanE. Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol2013;162:783791.

    • Search Google Scholar
    • Export Citation
  • 70.

    VerstovsekSMesaRAGotlibJ. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med2012;366:799807.

  • 71.

    HarrisonCKiladjianJJAl-AliHK. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med2012;366:787798.

    • Search Google Scholar
    • Export Citation
  • 72.

    MeadAJMilojkovicDKnapperS. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol2015;170:2939.

    • Search Google Scholar
    • Export Citation
  • 73.

    TavaresRPalumboGALe CoutreP. Safety and efficacy of ruxolitinib in an 1869-patient cohort of JUMP: an open-label, multicenter, single-arm, expanded-access study in patients with myelofibrosis [abstract]. Blood2015;126:Abstract 2799.

    • Search Google Scholar
    • Export Citation
  • 74.

    DavisKLKayeJACoteI. Real-world assessment of clinical outcomes in lower-risk myelofibrosis patients receiving treatment with ruxolitinib [abstract[. Blood2014;124:Abstract 1857.

    • Search Google Scholar
    • Export Citation
  • 75.

    VerstovsekSMesaRAGotlibJ. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica2015;100:479488.

    • Search Google Scholar
    • Export Citation
  • 76.

    GuptaVVerstovsekSMesaRA. Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I [abstract]. J Clin Oncol2016;34(15 Suppl):Abstract 7012.

    • Search Google Scholar
    • Export Citation
  • 77.

    CervantesFVannucchiAMKiladjianJJ. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122:40474053.

    • Search Google Scholar
    • Export Citation
  • 78.

    HarrisonCNVannucchiAMKiladjianJJ. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia2016;30:17011707.

    • Search Google Scholar
    • Export Citation
  • 79.

    VerstovsekSMesaRAGotlibJ. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis. Br J Haematol2013;161:508516.

    • Search Google Scholar
    • Export Citation
  • 80.

    VannucchiAMKantarjianHMKiladjianJJ. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica2015;100:11391145.

    • Search Google Scholar
    • Export Citation
  • 81.

    HeineABrossartPWolfD. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?Blood2013;122:38433844.

    • Search Google Scholar
    • Export Citation
  • 82.

    WyshamNGSullivanDRAlladaG. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest2013;143:14781479.

    • Search Google Scholar
    • Export Citation
  • 83.

    ShamilECunninghamDWongBLJaniP. Ruxolitinib associated tuberculosis presenting as a neck lump. Case Rep Infect Dis2015;2015:284168.

  • 84.

    WathesRMouleSMilojkovicD. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med2013;369:197198.

  • 85.

    CaocciGMurgiaFPoddaL. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia2014;28:225227.

    • Search Google Scholar
    • Export Citation
  • 86.

    ShenCHHwangCEChenYYChenCC. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol2014;93:10751076.

  • 87.

    TongLXJacksonJKerstetterJWorswickSD. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol2014;70:e5960.

    • Search Google Scholar
    • Export Citation
  • 88.

    GuglielmelliPBiamonteFRotunnoG. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood2014;123:21572160.

    • Search Google Scholar
    • Export Citation
  • 89.

    PatelKPNewberryKJLuthraR. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood2015;126:790797.

    • Search Google Scholar
    • Export Citation
  • 90.

    DeegHJBredesonCFarniaS. Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all age groups. Biol Blood Marrow Transplant2015;21:18831887.

    • Search Google Scholar
    • Export Citation
  • 91.

    BallenKKShresthaSSobocinskiKA. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant2010;16:358367.

  • 92.

    SnyderDSPalmerJSteinAS. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant2006;12:11611168.

    • Search Google Scholar
    • Export Citation
  • 93.

    KrogerNHollerEKobbeG. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood2009;114:52645270.

    • Search Google Scholar
    • Export Citation
  • 94.

    PatriarcaFBacigalupoASperottoA. Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. experience. Mediterr J Hematol Infect Dis2010;2:e2010010.

    • Search Google Scholar
    • Export Citation
  • 95.

    SnyderDSPalmerJGaalK. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant2010;16:281286.

    • Search Google Scholar
    • Export Citation
  • 96.

    GuptaVMaloneAKHariPN. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant2014;20:8997.

    • Search Google Scholar
    • Export Citation
  • 97.

    LussanaFRambaldiAFinazziMC. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica2014;99:916921.

    • Search Google Scholar
    • Export Citation
  • 98.

    RondelliDGoldbergJDIsolaL. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood2014;124:11831191.

    • Search Google Scholar
    • Export Citation
  • 99.

    RobinMPorcherRWolschkeC. Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis. Biol Blood Marrow Transplant2016;22:12061211.

    • Search Google Scholar
    • Export Citation
  • 100.

    ScottBLGooleyTASorrorML. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood2012;119:26572664.

    • Search Google Scholar
    • Export Citation
  • 101.

    AlchalbyHYunusDRZabelinaT. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol2012;157:7585.

    • Search Google Scholar
    • Export Citation
  • 102.

    KrogerNGiorginoTScottBL. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood2015;125:33473350;quiz 3364.

    • Search Google Scholar
    • Export Citation
  • 103.

    TalpazMPaquetteRAfrinL. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol2013;6:81.

    • Search Google Scholar
    • Export Citation
  • 104.

    MesaRACortesJ. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol2013;6:79.

    • Search Google Scholar
    • Export Citation
  • 105.

    TefferiAPardananiA. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc2011;86:11881191.

    • Search Google Scholar
    • Export Citation
  • 106.

    DeiningerMRadichJBurnTC. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood2015;126:15511554.

    • Search Google Scholar
    • Export Citation
  • 107.

    AlchalbyHBadbaranAZabelinaT. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood2010;116:35723581.

    • Search Google Scholar
    • Export Citation
  • 108.

    LangeTEdelmannASieboltsU. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica2013;98:722728.

    • Search Google Scholar
    • Export Citation
  • 109.

    TefferiALashoTLJimmaT. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc2012;87:2533.

  • 110.

    CervantesFAlvarez-LarranAHernandez-BoludaJC. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol2004;127:399403.

    • Search Google Scholar
    • Export Citation
  • 111.

    CervantesFAlvarez-LarranAHernandez-BoludaJC. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol2006;134:184186.

    • Search Google Scholar
    • Export Citation
  • 112.

    TsiaraSNChaidosABourantasLK. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta Haematol2007;117:156161.

    • Search Google Scholar
    • Export Citation
  • 113.

    McMullinMFHarrisonCNNiederwieserD. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol2015;4:26.

    • Search Google Scholar
    • Export Citation
  • 114.

    HuangJTefferiA. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol2009;83:154155.

    • Search Google Scholar
    • Export Citation
  • 115.

    CervantesFIsolaIMAlvarez-LarranA. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol2015;94:17911796.

    • Search Google Scholar
    • Export Citation
  • 116.

    BarosiGElliottMCanepaL. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma2002;43:23012307.

    • Search Google Scholar
    • Export Citation
  • 117.

    ElliottMAMesaRALiCY. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol2002;117:288296.

  • 118.

    MerupMKuttiJBirgergardG. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol2002;19:7986.

    • Search Google Scholar
    • Export Citation
  • 119.

    MarchettiMBarosiGBalestriF. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol2004;22:424431.

    • Search Google Scholar
    • Export Citation
  • 120.

    StruppCGermingUSchererA. Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol2004;72:5257.

  • 121.

    ThomasDAGilesFJAlbitarM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer2006;106:19741984.

  • 122.

    AbgrallJFGuibaudIBastieJN. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica2006;91:10271032.

    • Search Google Scholar
    • Export Citation
  • 123.

    MesaRASteensmaDPPardananiA. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood2003;101:25342541.

    • Search Google Scholar
    • Export Citation
  • 124.

    TefferiACortesJVerstovsekS. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood2006;108:11581164.

  • 125.

    Quintas-CardamaAKantarjianHMManshouriT. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol2009;27:47604766.

    • Search Google Scholar
    • Export Citation
  • 126.

    MesaRAYaoXCripeLD. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood2010;116:44364438.

    • Search Google Scholar
    • Export Citation
  • 127.

    ChiharaDMasarovaLNewberryKJ. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res2016;48:15.

    • Search Google Scholar
    • Export Citation
  • 128.

    JabbourEThomasDKantarjianH. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood2011;118:899902.

  • 129.

    TefferiALashoTLMesaRA. Lenalidomide therapy in del(5) (q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia2007;21:18271828.

    • Search Google Scholar
    • Export Citation
  • 130.

    TamCSKantarjianHCortesJ. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol2009;27:55875593.

    • Search Google Scholar
    • Export Citation
  • 131.

    AbdulkarimKGirodonFJohanssonP. AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol2009;82:106111.

    • Search Google Scholar
    • Export Citation
  • 132.

    NielsenIHasselbalchHC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol2003;74:2631.

    • Search Google Scholar
    • Export Citation
  • 133.

    KiladjianJJChevretSDosquetC. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol2011;29:39073913.

    • Search Google Scholar
    • Export Citation
  • 134.

    BjorkholmMDerolfARHultcrantzM. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol2011;29:24102415.

    • Search Google Scholar
    • Export Citation
  • 135.

    NoorSJTanWWildingGE. Myeloid blastic transformation of myeloproliferative neoplasms—a review of 112 cases. Leuk Res2011;35:608613.

    • Search Google Scholar
    • Export Citation
  • 136.

    Quintas-CardamaAKantarjianHPierceS. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk2013;13:315318.

    • Search Google Scholar
    • Export Citation
  • 137.

    KlampflTHarutyunyanABergT. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood2011;118:167176.

    • Search Google Scholar
    • Export Citation
  • 138.

    MesaRALiCYKetterlingRP. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood2005;105:973977.

    • Search Google Scholar
    • Export Citation
  • 139.

    TamCSNussenzveigRMPopatU. The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood2008;112:16281637.

    • Search Google Scholar
    • Export Citation
  • 140.

    KennedyJAAtenafuEGMessnerHA. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood2013;121:27252733.

    • Search Google Scholar
    • Export Citation
  • 141.

    MascarenhasJNavadaSMaloneA. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res2010;34:12461249.

  • 142.

    ThepotSItzyksonRSeegersV. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood2010;116:37353742.

    • Search Google Scholar
    • Export Citation
  • 143.

    BadarTKantarjianHMRavandiF. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res2015;39:950956.

    • Search Google Scholar
    • Export Citation
  • 144.

    CiureaSOde LimaMGiraltS. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant2010;16:555559.

    • Search Google Scholar
    • Export Citation
  • 145.

    CheringtonCSlackJLLeisJ. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res2012;36:11471151.

    • Search Google Scholar
    • Export Citation
  • 146.

    AlchalbyHZabelinaTStubigT. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant2014;20:279281.

    • Search Google Scholar
    • Export Citation
  • 147.

    ShanavasMPopatUMichaelisLC. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus Kinase 1/2 inhibitors. Biol Blood Marrow Transplant2016;22:432440.

    • Search Google Scholar
    • Export Citation
  • 148.

    CervantesF. How I treat myelofibrosis. Blood2014;124:26352642.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 878 777 81
PDF Downloads 362 340 33
EPUB Downloads 0 0 0